Amphastar licenses three novel peptides from Anji for up to $453M total

Amphastar Pharmaceuticals, Inc.

Exclusive license for three proprietary peptides targeting oncology and ophthalmology in U.S. and Canada.
First asset: endogenous peptide suppressing multiple cancer types; second: novel peptide-docetaxel conjugate; third: topical VEGFR eye drop for wet AMD.
Upfront $6M ($0.75M earnest + $5.25M), development milestones up to $42M, sales milestones up to $225M, royalties capped at $60M per product.
Anji receives non-exclusive license outside territory; pays Amphastar low single-digit royalties on certain net sales.
Term: 10 years from first commercial sale per product; Amphastar can extend up to additional 10 years or patent expiry.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.